Diagnostic Testing
Prognostic Assessment
Therapeutic Monitoring
Minimal Residual Disease (MRD) Detection
Companion Diagnostics
The AML biomarker testing market's application landscape is primarily driven by the increasing need for precise diagnostic tools, which facilitate early detection and accurate classification of AML subtypes. Diagnostic testing remains the dominant segment, owing to the critical role of biomarker panels in differentiating AML from other hematological malignancies, thereby guiding initial treatment decisions. Prognostic assessment leverages biomarker data to stratify patients based on risk, influencing treatment intensity and monitoring strategies. Therapeutic monitoring, especially tracking minimal residual disease, is gaining prominence as therapies become more targeted, enabling clinicians to adapt treatment plans dynamically. The integration of biomarker testing into companion diagnostics further accelerates personalized medicine approaches, aligning targeted therapies with specific genetic mutations, thus improving outcomes and reducing adverse effects.
Each application segment reflects a different facet of AML management, with technological advancements and regulatory approvals shaping their growth trajectories. The increasing adoption of next-generation sequencing (NGS) and digital PCR techniques enhances the sensitivity and specificity of biomarker detection, enabling real-time disease monitoring and risk stratification. The evolving landscape of AML treatment, characterized by the advent of targeted agents such as FLT3 inhibitors and IDH1/2 inhibitors, underscores the importance of comprehensive biomarker profiling. As clinical guidelines increasingly endorse biomarker-driven approaches, the application segments are poised for sustained expansion, driven by the imperative for precision oncology and the integration of biomarker testing into routine clinical workflows.
Genetic Mutation Testing
Protein Biomarker Testing
Gene Expression Profiling
Epigenetic Marker Testing
The type segmentation within the AML biomarker testing market reflects the technological diversity and specificity required for comprehensive disease characterization. Genetic mutation testing, focusing on mutations such as FLT3, NPM1, and IDH1/2, remains the cornerstone of molecular diagnostics, directly influencing targeted therapy selection. Protein biomarker testing complements genetic data by providing insights into disease activity and prognosis, often through immunohistochemistry or ELISA-based assays. Gene expression profiling offers a broader understanding of cellular pathways involved in AML pathogenesis, aiding in subclassification and risk assessment. Epigenetic marker testing, including DNA methylation and histone modification analysis, is emerging as a vital component for understanding disease heterogeneity and resistance mechanisms. The convergence of these types, supported by advancements in multiplexed assays and bioinformatics, is transforming AML diagnostics into a multi-dimensional, highly precise discipline.
Each biomarker type offers unique insights, with genetic mutation testing leading the market due to its direct therapeutic implications. However, the integration of protein and epigenetic markers is expanding the diagnostic toolkit, enabling more nuanced patient stratification. The future of AML biomarker testing hinges on the development of integrated platforms that combine multiple biomarker types, thereby providing a comprehensive disease profile that informs personalized treatment strategies and improves clinical outcomes.
Get the full PDF sample copy of the report: (Includes full table of contents, list of tables and figures, and graphs):- https://www.verifiedmarketreports.com/download-sample/?rid=876178/?utm_source=G-S-MAYNSB1&utm_medium=359&utm_country=Global
Market size (2024): USD 1.2 Billion
Forecast (2033): USD 4.5 Billion
CAGR 2026-2033: 15.2%
Leading Segments: Genetic mutation testing and prognostic assessment
Existing & Emerging Technologies: Next-generation sequencing (NGS), digital PCR, and epigenetic assays
Leading Regions/Countries & why: North America and Europe, due to high R&D investment, advanced healthcare infrastructure, and favorable regulatory environment
Major Companies: QIAGEN, F. Hoffmann-La Roche, Thermo Fisher Scientific, Invitae Corporation, and NeoGenomics
North America dominates the AML biomarker testing market, driven by technological innovation, high healthcare expenditure, and rapid adoption of personalized medicine.
Europe is witnessing accelerated growth owing to supportive regulatory frameworks and increasing clinical trial activity focused on targeted therapies.
Asia Pacific presents significant growth opportunities, fueled by expanding healthcare infrastructure, rising AML prevalence, and increasing awareness of molecular diagnostics.
Emerging players are innovating in multiplexed testing platforms, integrating multi-omics data for comprehensive AML profiling.
Regulatory approvals for novel biomarker panels and companion diagnostics are catalyzing market expansion across developed and developing regions.
Artificial intelligence (AI) is revolutionizing AML biomarker testing by enhancing data analysis, biomarker discovery, and predictive modeling. Machine learning algorithms process vast genomic and proteomic datasets, identifying novel biomarkers with higher accuracy and speed than traditional methods. AI-driven diagnostics facilitate real-time disease monitoring, enabling clinicians to tailor therapies dynamically, thereby improving patient outcomes and reducing treatment costs. Furthermore, AI enhances the integration of multi-omics data, supporting the development of comprehensive biomarker panels that capture disease heterogeneity more effectively. This technological evolution is critical as AML treatment becomes increasingly personalized, with AI serving as a catalyst for rapid, precise diagnostics and therapeutic decision-making.
The geopolitical landscape significantly influences the AML biomarker testing market through factors such as trade policies, research funding, and regulatory harmonization. Countries with stable political environments and strong biotech ecosystems, like the US and Germany, are leading innovation and commercialization efforts. Conversely, geopolitical tensions and trade restrictions can impede supply chains, limit access to cutting-edge technologies, and slow regulatory approvals, especially in emerging markets. The ongoing US-China trade tensions, for example, pose risks to supply chain resilience for critical reagents and instrumentation. Conversely, regional collaborations and international regulatory convergence, such as the FDA and EMA harmonization initiatives, are expected to accelerate market growth and technology adoption globally. Forward-looking, the market will likely see increased AI-driven diagnostics supported by strategic alliances, with geopolitical stability serving as a key enabler for sustained innovation and market expansion.
Potential scenarios include accelerated growth in regions fostering innovation-friendly policies and investments, while geopolitical conflicts could introduce supply chain disruptions and regulatory delays. Stakeholders should prioritize diversification of supply sources, strategic partnerships, and compliance with evolving international standards to mitigate risks and capitalize on emerging opportunities.
The AML biomarker testing market was valued at USD 1.2 Billion in 2024 and is poised to grow from USD 1.4 Billion in 2025 to USD 4.5 Billion by 2033, expanding at a CAGR of 15.2% during 2026-2033. Key drivers include the increasing adoption of targeted therapies, advancements in molecular diagnostics, and regulatory approvals for novel biomarker panels. The market's growth is predominantly fueled by the rising prevalence of AML globally, technological innovations in genomics and proteomics, and the integration of AI-driven diagnostics into clinical workflows. The application spectrum is broadening, with diagnostic, prognostic, and minimal residual disease testing leading the demand, supported by the shift toward personalized medicine.
This comprehensive market research report offers strategic insights into the evolving landscape of AML biomarker testing, providing stakeholders with data-driven forecasts, competitive positioning, and actionable intelligence. It synthesizes industry dynamics, technological trends, and regional variations, enabling decision-makers to identify growth opportunities, optimize R&D investments, and navigate regulatory complexities effectively. Delivered through detailed dashboards, executive summaries, and in-depth analysis, this report aims to empower investors, biotech firms, and healthcare providers with a nuanced understanding of the future trajectory of AML biomarker diagnostics.
Claim Your Offer for This Report @ https://www.verifiedmarketreports.com/ask-for-discount/?rid=876178/?utm_source=G-S-MAYNSB1&utm_medium=359&utm_country=Global
The convergence of genomics, transcriptomics, proteomics, and epigenomics is transforming AML diagnostics by enabling a holistic understanding of disease heterogeneity. Multi-omics platforms facilitate the identification of complex biomarker signatures that improve diagnostic accuracy, risk stratification, and therapeutic targeting. Driven by decreasing sequencing costs and advanced bioinformatics, this trend is supported by regulatory pathways favoring comprehensive diagnostic panels. The integration of multi-omics data into clinical workflows enhances personalized treatment plans, especially in identifying resistance mechanisms and predicting relapse. The monetization impact is significant, as multi-omics approaches command premium pricing and foster new service models in precision oncology.
Drivers include declining sequencing costs, increasing data complexity, and regulatory acceptance of multi-analyte panels.
Enabling technologies encompass high-throughput sequencing, advanced bioinformatics, and cloud-based data analytics.
Regulatory catalysts include FDA approvals for multi-omics diagnostic platforms and evolving clinical guidelines.
Competitive shifts favor integrated service providers and biotech firms investing in multi-omics R&D.
Use-case evolution involves comprehensive disease profiling, resistance monitoring, and therapy selection.
AI algorithms are increasingly embedded in biomarker discovery, data interpretation, and clinical decision support, significantly reducing diagnostic turnaround times and improving accuracy. Machine learning models trained on large genomic datasets identify novel mutation patterns and biomarker combinations that elude traditional analysis. This technological shift is supported by advancements in natural language processing (NLP) and deep learning, which enhance the interpretation of complex clinical and molecular data. AI's role in predictive analytics enables early intervention, better risk stratification, and dynamic monitoring of minimal residual disease. The monetization of AI-enabled platforms is accelerating, with major vendors integrating AI into their diagnostic pipelines, creating new revenue streams and competitive advantages.
Drivers include increasing data volume, need for rapid diagnostics, and demand for personalized treatment.
Technologies involve deep learning, NLP, and predictive modeling integrated into diagnostic workflows.
Regulatory support is emerging through FDA approvals of AI-based diagnostic tools.
Market shifts favor tech-savvy diagnostic companies and collaborations between AI firms and biotech developers.
Use cases extend to real-time disease monitoring, relapse prediction, and therapy optimization.
Global regulatory convergence is streamlining the approval process for novel AML biomarker tests, reducing time-to-market and facilitating broader adoption. Initiatives like the FDA’s breakthrough device designation and EMA’s adaptive pathways are encouraging innovation by providing expedited review pathways for high-impact diagnostics. This regulatory environment incentivizes R&D investments, especially in emerging biomarker panels and companion diagnostics aligned with targeted therapies. The impact on market dynamics includes increased competition, faster commercialization cycles, and enhanced trust in diagnostic accuracy. As regulators increasingly endorse multi-omics and AI-integrated platforms, the market will witness accelerated innovation and deployment, especially in developed regions.
Drivers include regulatory incentives, evolving clinical guidelines, and patient safety considerations.
Technologies supported by regulatory pathways include multiplexed assays, AI diagnostics, and digital health integration.
Competitive positioning shifts toward early adopters of regulatory approvals and innovative platforms.
Use-case evolution involves rapid deployment in clinical trials and routine diagnostics.
Liquid biopsy techniques, utilizing circulating tumor DNA (ctDNA) and other biomarkers in blood, are gaining traction as minimally invasive alternatives to traditional tissue biopsies. Advances in digital PCR and NGS enable high-sensitivity detection of AML-specific mutations, facilitating early diagnosis, real-time monitoring, and relapse detection. The non-invasive nature reduces procedural risks and enhances patient compliance, especially in longitudinal studies. This trend is supported by regulatory approvals for liquid biopsy-based companion diagnostics and increasing clinical validation. The monetization potential is substantial, as liquid biopsy tests command premium pricing and open new markets in outpatient settings. As technology matures, liquid biopsy is poised to become a standard component of AML management, complementing tissue-based assays and expanding diagnostic reach.
Drivers include patient preference, technological advancements, and clinical validation.
Enabling tech includes ultra-sensitive NGS, digital PCR, and microfluidics.
Regulatory catalysts involve approvals for liquid biopsy-based diagnostics and companion tests.
Market shifts favor companies investing in liquid biopsy platforms and integrated testing solutions.
Use cases encompass early detection, minimal residual disease monitoring, and relapse prediction.
The US AML biomarker testing market was valued at USD 0.6 Billion in 2024 and is projected to grow from USD 0.7 Billion in 2025 to USD 2.2 Billion by 2033, with a CAGR of 15.4%. The market is propelled by high healthcare expenditure, a robust biotech ecosystem, and rapid adoption of precision medicine. Leading segments include genetic mutation testing and MRD detection, driven by extensive clinical research and regulatory approvals. Major players like QIAGEN and Roche dominate the landscape, leveraging advanced NGS platforms and companion diagnostics. The US market benefits from a favorable regulatory environment, substantial R&D investments, and a high prevalence of AML, which collectively foster innovation and commercialization. Challenges include reimbursement complexities and the need for standardization across diverse healthcare providers, but overall, the market’s growth prospects remain strong due to technological and clinical advancements.
Japan’s AML biomarker testing market was valued at USD 0.2 Billion in 2024 and is expected to grow from USD 0.24 Billion in 2025 to USD 0.75 Billion by 2033, at a CAGR of 15.0%. The market’s expansion is driven by increasing adoption of molecular diagnostics, government initiatives supporting personalized medicine, and rising AML incidence. Key segments include genetic mutation testing and epigenetic assays, with local companies collaborating with global firms to enhance technological capabilities. Japan’s advanced healthcare infrastructure and regulatory support facilitate rapid approval and deployment of innovative diagnostics. The main challenges involve high costs and reimbursement hurdles, but the country’s focus on aging populations and precision oncology positions it as a significant growth hub for AML biomarker testing innovation.
South Korea’s AML biomarker testing market was valued at USD 0.15 Billion in 2024 and is projected to reach USD 0.45 Billion by 2033, growing at a CAGR of 14.8%. The market’s growth is fueled by government investments in biotech R&D, increasing clinical trials, and rising awareness of molecular diagnostics. Leading segments include gene mutation profiling and MRD testing, supported by local biotech startups and multinational collaborations. The country’s strategic focus on digital health and AI integration enhances diagnostic accuracy and operational efficiency. Challenges include regulatory delays and reimbursement policies, but the overall outlook remains positive due to technological innovation and expanding healthcare access.
The UK AML biomarker testing market was valued at USD 0.12 Billion in 2024 and is expected to grow from USD 0.14 Billion in 2025 to USD 0.4 Billion by 2033, at a CAGR of 14.5%. The growth drivers include government-funded research initiatives, adoption of advanced diagnostics, and increasing AML cases. Key segments involve genetic mutation panels and liquid biopsy solutions, with leading companies like Invitae and NeoGenomics expanding their UK footprint. The UK benefits from a supportive regulatory environment, NHS integration, and a focus on clinical innovation. Challenges include cost containment pressures and variability in healthcare infrastructure, but the market’s trajectory remains upward due to technological advancements and strategic collaborations.
Germany’s AML biomarker testing market was valued at USD 0.2 Billion in 2024 and is projected to grow to USD 0.65 Billion by 2033, with a CAGR of 15.2%. The market’s expansion is driven by strong R&D activity, high healthcare expenditure, and a well-established biotech sector. Leading segments include comprehensive genetic panels and epigenetic testing, supported by collaborations between academia and industry. Germany’s regulatory framework facilitates swift approval of innovative diagnostics, and its central role within the EU accelerates market access across Europe. Challenges involve reimbursement policies and the need for standardization, but overall, the market benefits from technological leadership and a focus on personalized medicine.
In March 2025, QIAGEN launched a next-generation NGS panel designed specifically for AML mutation profiling, enhancing detection sensitivity and turnaround time for clinical labs.
In April 2025, Roche announced a strategic partnership with a biotech startup to develop AI-powered diagnostic algorithms for MRD detection, aiming to improve predictive accuracy and clinical utility.
In June 2025, Invitae completed the acquisition of a regional molecular diagnostics firm, expanding its portfolio and geographic reach in Asia-Pacific markets.
In July 2025, Thermo Fisher Scientific introduced a comprehensive liquid biopsy kit for AML, integrating digital PCR and NGS technologies to facilitate non-invasive disease monitoring.
In August 2025, a major regulatory milestone was achieved when the FDA approved a multiplexed biomarker panel for AML prognosis, setting a new standard for diagnostic validation.
In September 2025, a collaborative research initiative was announced between academic institutions and industry leaders to develop epigenetic biomarkers for AML resistance mechanisms.
In October 2025, a leading biotech firm secured funding for a clinical trial evaluating a multi-omics diagnostic platform, aiming to revolutionize AML risk stratification.
The AML biomarker testing market is characterized by a mix of global giants, regional innovators, and emerging startups, each leveraging distinct strategic strengths. Major players such as QIAGEN, Roche, Thermo Fisher Scientific, Invitae, and NeoGenomics dominate through extensive R&D investments, broad product portfolios, and established distribution channels. These companies focus on integrating multi-omics, AI, and liquid biopsy technologies to maintain competitive advantage, often engaging in strategic acquisitions and collaborations to accelerate innovation. Regional leaders are also emerging, especially in Asia-Pacific, where local firms are gaining ground through tailored solutions and cost-effective offerings. The competitive landscape is highly dynamic, with innovation, regulatory agility, and strategic alliances serving as key differentiators. Revenue benchmarks over the past five years reflect a consistent upward trajectory, with R&D expenditure averaging around 10-15% of revenues, emphasizing a focus on technological leadership and pipeline expansion.
The primary drivers of the AML biomarker testing market include the rising global incidence of AML, which necessitates more precise diagnostic and monitoring tools. Advances in genomic sequencing technologies, particularly NGS, have drastically reduced costs and increased throughput, making comprehensive biomarker panels more accessible. The shift toward personalized medicine, driven by targeted therapies such as FLT3 inhibitors and IDH1/2 inhibitors, underscores the need for detailed molecular profiling to optimize treatment strategies. Regulatory approvals for novel biomarker panels and companion diagnostics further catalyze market expansion, as they provide validation and confidence for clinicians and payers. Additionally, increasing clinical trial activity focusing on biomarker-driven therapies accelerates the development and adoption of innovative testing solutions, creating a fertile environment for sustained growth.
Growing AML prevalence globally, especially among aging populations, necessitates advanced diagnostics.
Technological advancements in NGS, digital PCR, and bioinformatics reduce costs and improve accuracy.
Regulatory support and approval pathways for new biomarker panels facilitate faster market entry.
Expansion of targeted therapies increases demand for comprehensive molecular profiling.
Integration of AI enhances diagnostic precision and predictive analytics, driving clinical confidence.
Despite positive growth prospects, several restraints challenge the AML biomarker testing market. High costs associated with advanced diagnostic platforms and consumables limit adoption in cost-sensitive healthcare settings, particularly in emerging markets. Reimbursement uncertainties and variable coverage policies hinder widespread implementation, especially for novel or off-label biomarker panels. The lack of standardized testing protocols and inter-laboratory variability pose challenges to clinical validation and regulatory approval processes. Moreover, the complexity of AML’s molecular landscape, with its heterogeneity and evolving resistance mechanisms, complicates biomarker panel design and interpretation. Data privacy concerns and regulatory hurdles related to AI and digital health integration further slow deployment, necessitating robust validation and compliance frameworks to foster trust and adoption.
High costs of advanced diagnostics restrict access in low-resource healthcare systems.
Reimbursement policies lag behind technological innovations, creating financial barriers.
Standardization issues and inter-laboratory variability impact clinical validation and regulatory approval.
AML’s molecular heterogeneity complicates biomarker panel development and interpretation.
Data privacy and AI regulatory concerns hinder rapid deployment of digital diagnostics.
Development of integrated multi-omics platforms combining genomics, epigenetics, and proteomics for comprehensive AML profiling.
Expansion of liquid biopsy applications for early detection, minimal residual disease monitoring, and relapse prediction.
Adoption of AI-driven diagnostics to enhance predictive accuracy, streamline workflows, and enable real-time decision support.
Regional market expansion in Asia-Pacific and Latin America driven by increasing healthcare investments and AML prevalence.
Collaborations between biotech firms, academic institutions, and regulatory agencies to accelerate innovation and approval processes.
The AML biomarker testing market is positioned for robust growth driven by technological innovation, expanding clinical applications, and evolving regulatory landscapes. Scenario-based forecasts suggest that the market could reach USD 4.5 billion by 2033, with a CAGR of approximately 15.2%, contingent upon regulatory harmonization and reimbursement reforms. Capital deployment will likely favor integrated multi-omics and AI-enabled diagnostic platforms, with strategic M&A activity accelerating consolidation and innovation. Stakeholders should prioritize investments in liquid biopsy technologies, digital health integration, and regional market entry strategies to capitalize on emerging opportunities. Risk factors include regulatory delays, reimbursement uncertainties, and geopolitical disruptions affecting supply chains and R&D collaborations. A balanced approach emphasizing innovation, compliance, and regional diversification will be essential for sustained growth and competitive advantage in this evolving landscape.
The research methodology underpinning this report integrates primary and secondary data sources, including proprietary surveys, syndicated databases, patent filings, financial disclosures, and expert interviews. Data collection involved targeted sampling quotas across key regions, with adjustments for non-response bias and weighting schemas to ensure representativeness. Advanced analytics employed include NLP pipelines for sentiment analysis, LDA/BERTopic for thematic clustering, causal inference models for trend validation, and machine learning algorithms for forecasting. Validation protocols encompass holdout testing, back-testing, sensitivity analysis, and reproducibility checks, ensuring robustness and accuracy. Ethical considerations adhere to global standards, including informed consent governance, transparency in synthetic data use, and AI model auditability, fostering trust and compliance across jurisdictions.
What are the main applications of AML biomarker testing?
AML biomarker testing is primarily used for diagnosis, prognosis, therapeutic monitoring, minimal residual disease detection, and companion diagnostics.
Which technologies are most commonly used in AML biomarker testing?
Next-generation sequencing (NGS), digital PCR, and epigenetic assays are the leading technologies employed for AML biomarker detection.
How does AI impact AML biomarker diagnostics?
AI enhances data analysis, biomarker discovery, and predictive modeling, leading to faster, more accurate diagnostics and personalized treatment plans.
What regions are leading in AML biomarker testing adoption?
North America and Europe lead due to high healthcare spending, advanced infrastructure, and regulatory support, with Asia-Pacific rapidly catching up.
What are the main challenges facing the AML biomarker testing market?
High costs, reimbursement issues, lack of standardization, molecular heterogeneity, and regulatory hurdles are key challenges.
What future trends are shaping AML biomarker testing?
Integration of multi-omics, liquid biopsy expansion, AI-driven diagnostics, and regulatory harmonization are major future trends.
Which companies are the key players in this market?
Leading companies include QIAGEN, Roche, Thermo Fisher Scientific, Invitae, and NeoGenomics, among others.
What is the market size forecast for 2033?
The market is projected to reach USD 4.5 billion by 2033, with a CAGR of around 15.2% from 2026 to 2033.
How are regulatory developments influencing the market?
Regulatory approvals and harmonization accelerate product commercialization, fostering innovation and wider adoption.
What role does regional variation play in market growth?
Regional differences in healthcare infrastructure, regulatory environment, and AML prevalence significantly influence market dynamics and growth opportunities.
Curious to know more? Visit: @ https://www.verifiedmarketreports.com/product/acute-myeloid-leukemia-aml-biomarker-testing-market/
1. INTRODUCTION
1.1 MARKET DEFINITION AND SCOPE
1.2 MARKET TAXONOMY AND INDUSTRY CLASSIFICATION
1.3 INCLUSION AND EXCLUSION CRITERIA
1.4 MARKET SEGMENTATION FRAMEWORK
1.5 RESEARCH OBJECTIVES
1.6 RESEARCH TIMELINES AND STUDY PERIOD
1.7 CURRENCY, PRICING, AND INFLATION ASSUMPTIONS
1.8 STAKEHOLDER MAPPING (SUPPLY SIDE VS DEMAND SIDE)
1.9 LIMITATIONS AND RISK CONSIDERATIONS
1.10 KEY TERMINOLOGIES AND ABBREVIATIONS
2. RESEARCH METHODOLOGY
2.1 RESEARCH DESIGN AND APPROACH
2.2 DATA MINING AND DATA ACQUISITION MODELS
2.3 SECONDARY RESEARCH (PAID DATABASES, INDUSTRY JOURNALS, REGULATORY FILINGS)
2.4 PRIMARY RESEARCH (KOL INTERVIEWS, CXO INSIGHTS, CHANNEL PARTNERS)
2.5 EXPERT VALIDATION AND SUBJECT MATTER ADVISORY
2.6 DATA TRIANGULATION METHODOLOGY
2.7 MARKET SIZE ESTIMATION MODELS
2.7.1 BOTTOM-UP APPROACH
2.7.2 TOP-DOWN APPROACH
2.7.3 DEMAND-SIDE MODELING
2.7.4 SUPPLY-SIDE MODELING
2.8 FORECASTING METHODOLOGY (TIME-SERIES, REGRESSION, SCENARIO-BASED)
2.9 SENSITIVITY AND SCENARIO ANALYSIS (BEST CASE, BASE CASE, WORST CASE)
2.10 QUALITY ASSURANCE AND DATA VALIDATION
2.11 RESEARCH FLOW AND PROCESS FRAMEWORK
2.12 DATA TYPES AND SOURCES (QUANTITATIVE VS QUALITATIVE)
3. EXECUTIVE SUMMARY
3.1 GLOBAL ACUTE MYELOID LEUKEMIA (AML) BIOMARKER TESTING MARKET SNAPSHOT
3.2 KEY INSIGHTS AND STRATEGIC